Posted by Michael Wonder on 02 Jun 2017
Transparency Commission revises ASMR for Imbruvica
1 June 2017 - The Transparency Commission has published its revised opinion on the ASMR for ibrutinib for patients with mantle cell lymphoma.
The Transparency Commission first considered ibrutinib for patients with mantle cell lymphoma in June 2015. The Commission gave it an ASMR of IV.
The Commission conducted a review of its June 2015 opinion last month and has revised the ASMR to a III.
Read Transparency Commission 2017 opinion for ibrutinib [French]
